Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor–positive, HER2-negative advanced or metastatic bre
The real-world survival outcomes found in this study for patients receiving first-/second-line CDK4/6i therapy were consistent with those of randomized phase 3 studies. As outcomes of subsequent treatment after initial CDK4/6i plus ET remain insufficient, further improvement in treatment is necessary.
Authors
- Yuko Takano (ORCID: https://orcid.org/0000-0002-3753-7683)
- Yasuaki Sagara (ORCID: https://orcid.org/0000-0001-5705-1739)
- Nobuyuki Sekine
- Nobuhiro Shibata (ORCID: https://orcid.org/0000-0001-8647-5098)
- Yukiko Kajiwara
- Shigehira Saji (ORCID: https://orcid.org/0000-0002-6732-8030)
- Fumie Fujisawa (ORCID: https://orcid.org/0000-0001-8436-9072)
- Masahiro Takada (ORCID: https://orcid.org/0000-0002-5954-1296)
- Hiroko Bando (ORCID: https://orcid.org/0000-0002-7361-3647)
- Naoko Toriguchi
- Tsutomu Kawaguchi (ORCID: https://orcid.org/0000-0001-6182-9005)
- Kazuhiko Yamagami
- Tetsuhiro Yoshinami (ORCID: https://orcid.org/0009-0000-8747-3641)
- Masami Tsukabe (ORCID: https://orcid.org/0009-0009-3284-0833)
- M. Yamamoto
- Norikazu Masuda (ORCID: https://orcid.org/0000-0002-7302-0278)
- Yukinori Ozaki (ORCID: https://orcid.org/0000-0002-8064-648X)
- Nobuyuki Tsunoda (ORCID: https://orcid.org/0000-0002-4993-0028)
- Kenichi Watanabe (ORCID: https://orcid.org/0000-0002-5269-146X)
- Satoshi Morita (ORCID: https://orcid.org/0000-0002-4344-3317)
- Shigenori E. Nagai (ORCID: https://orcid.org/0000-0003-2887-6066)
- Chiya Oshiro
- Kei Koizumi
Institutions
- Kansai Medical University (JP)
- Fukushima Medical University (JP)
- Hamamatsu University (JP)
- University of Tsukuba (JP)
- Kyoto University (JP)
- Hamamatsu University School of Medicine (JP)
- Nagoya University Hospital (JP)
- National Hospital Organization Hokkaido Medical Center (JP)
- Hiroshima City Asa Citizens Hospital (JP)
- Eli Lilly (Japan) (JP)
- National Sagamihara Hospital (JP)
- Saitama Cancer Center (JP)
- Japanese Red Cross Nagoya Daiichi Hospital (JP)
- The Cancer Institute Hospital (JP)
- Shinko Hospital (JP)
- Takarazuka City Hospital (JP)
- Shiga Medical Center (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Breast Cancer
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1007/s12282-025-01713-7
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Taiho Pharmaceutical
- Ministry of Health, Labour and Welfare
- Eisai
- Shionogi
- Novartis Pharma
- Chugai Pharmaceutical
- Eli Lilly Japan
- Daiichi Sankyo Europe